- Home
- GOSS vs DIAX Comparison
GOSS vs DIAX Comparison
Compare GOSS & DIAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- DIAX
- Stock Information
- Founded
- GOSS 2015
- DIAX 2005
- Country
- GOSS United States
- DIAX United States
- Employees
- GOSS N/A
- DIAX N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- DIAX Finance Companies
- Sector
- GOSS Health Care
- DIAX Finance
- Exchange
- GOSS Nasdaq
- DIAX Nasdaq
- Market Cap
- GOSS 501.2M
- DIAX 535.3M
- IPO Year
- GOSS 2019
- DIAX N/A
- Fundamental
- Price
- GOSS $2.37
- DIAX $14.87
- Analyst Decision
- GOSS Strong Buy
- DIAX
- Analyst Count
- GOSS 6
- DIAX 0
- Target Price
- GOSS $8.60
- DIAX N/A
- AVG Volume (30 Days)
- GOSS 3.0M
- DIAX 96.6K
- Earning Date
- GOSS 11-05-2025
- DIAX 01-01-0001
- Dividend Yield
- GOSS N/A
- DIAX 7.93%
- EPS Growth
- GOSS N/A
- DIAX N/A
- EPS
- GOSS N/A
- DIAX N/A
- Revenue
- GOSS $40,237,000.00
- DIAX N/A
- Revenue This Year
- GOSS N/A
- DIAX N/A
- Revenue Next Year
- GOSS $16.11
- DIAX N/A
- P/E Ratio
- GOSS N/A
- DIAX N/A
- Revenue Growth
- GOSS N/A
- DIAX N/A
- 52 Week Low
- GOSS $0.66
- DIAX $12.80
- 52 Week High
- GOSS $3.60
- DIAX $15.12
- Technical
- Relative Strength Index (RSI)
- GOSS 48.07
- DIAX 56.34
- Support Level
- GOSS $2.28
- DIAX $14.81
- Resistance Level
- GOSS $2.52
- DIAX $14.99
- Average True Range (ATR)
- GOSS 0.15
- DIAX 0.13
- MACD
- GOSS 0.02
- DIAX 0.01
- Stochastic Oscillator
- GOSS 62.79
- DIAX 75.51
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.